Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Guidelines on osteoporosis treatment poorly implemented in RA patients

11 Jan 2020

Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Of the patients who should have been treated with antiosteoporosis therapy, only 22.6 percent were actually treated according to the 2014 guidelines and 27.3 percent according to the 2003 guidelines. Of postmenopausal women, only 23.6 percent were treated according to the 2012 guidelines.

The implementation of the 2014 GIOP guidelines led to an increase in the theoretical number of patients requiring treatment compared to the 2003 GIOP guidelines (77 percent vs 53 percent; p<0.001).

Multivariable analysis demonstrated that being treated correlated with a spinal T score ≤–2 SD according to the 2014 guidelines, with not taking part in physical activity for >30 min/day according to the 2003 guidelines, and with older age, lower body mass index and a T score ≤–2.5 SD in at least one site according to the PMOP guidelines.

“The management of osteoporosis needs to be improved in this population,” the authors said.

This cross-sectional study included 776 patients with RA from 19 centres. The authors collected data required for the application of the various recommendations (eg, age, sex, prednisone intake, low-energy fracture, history of hip fractures in the immediate family and bone densitometry), antiosteoporotic drugs and the various factors that may be associated with the application of the recommendations.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.